About EpiBiome
EpiBiome is a Healthcare company based in San Francisco (United States) founded in 2013, and was acquired by Locus Biosciences in July 2018. Small-molecule antibiotics are developed for agriculture and human health. EpiBiome has raised $6 million across 6 funding rounds from investors including Illumina, SVB and ARE. Its focus areas include Life Sciences, Genomics, Applied Genomics and Synthetic Biology. Its competitors include Moderna, Adaptive Biotechnologies and Amyris; 3 of its 3 listed competitors have raised funding.
Company details
EpiBiome was founded in 2013 and is headquartered in San Francisco, United States. Antibiotics and phage-based therapeutics are developed by the company for applications in agriculture and human health. Large-scale automation, bioinformatics, and algorithmic methods are employed to create targeted treatments against pathogens, including those resistant to conventional antibiotics. Operations focus on precision in eliminating bacterial threats without broad-spectrum effects.
- Headquarters San Francisco, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website epibiome.com
- Social LinkedIn X Facebook
- Acquired by Locus Biosciences (Jul 2018)
- Total Equity Funding$6M (USD)
in 6 rounds
- Latest Funding Round$200K (USD), Grant
Jun 2017
- InvestorsIllumina
& 10 more
- Acquired byLocus Biosciences
(Jul 2018)
Funding Insights of EpiBiome
EpiBiome has successfully raised a total of $6M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $200 thousand completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6M
- Total Rounds 6
- Last Round Grant — $200,000
- Investors Count 10
All 6 funding rounds of EpiBiome with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2017 | $200,000 | Grant | – | – | |
| Jul 2016 | $400,000 | Grant | – | – | |
| Jun 2016 | $1M | Debt – Venture | – | – | |
| Nov 2015 | $100,000 | Grant | – | – | |
| Oct 2015 | $6M | Series A | – | – | |
| Oct 2014 | Seed | – | – |
11 investors in total: 11 institutional.
Investors in EpiBiome
EpiBiome has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Illumina, SVB and ARE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Startups are accelerated by Stanford-backed program in Palo Alto. | startx.com | Palo Alto, United States | ||
Early-stage ventures are funded by the investment firm. | matrix.vc | San Francisco, United States | ||
Private investment firm focused on multiple sectors | vikingglobal.com | Greenwich, United States | ||
Investments are directed toward seed-stage startups by CRCM Ventures. | crcmventures.com | San Francisco, United States | ||
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States | ||
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Life sciences and tech focused VC firm funding companies in the US and Israel | svtechventures.us | Palo Alto, United States | ||
Developer of technologies for analysis of genetic variation and function | 1993 | illumina.com | San Diego, United States |
Investor details for EpiBiome
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of EpiBiome
4 dated milestones of EpiBiome across 5 years, from founding to its latest funding, stage changes and deals.
- Founded EpiBiome is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $200K.
- Exit Acquired by Locus Biosciences.
Competitors of EpiBiome
EpiBiome has 3 listed competitors in our database, 3 of them funded. They include Moderna, Adaptive Biotechnologies and Amyris.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions |
Detailed competitors of EpiBiome
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as EpiBiome (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Epibiome
Complete news archive for EpiBiome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EpiBiome
EpiBiome was founded in 2013 and raised its 1st funding round 1 year after it was founded.
EpiBiome is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
EpiBiome is a funded company, having raised a total of $6M across 6 funding rounds to date.
EpiBiome was founded in 2013 and is headquartered in San Francisco, United States. Antibiotics and phage-based therapeutics are developed by the company for applications in agriculture and human health. Large-scale automation, bioinformatics, and algorithmic methods are employed to create targeted treatments against pathogens, including those resistant to conventional antibiotics. Operations focus on precision in eliminating bacterial threats without broad-spectrum effects.
EpiBiome's top competitors include Moderna, Adaptive Biotechnologies and Amyris.
EpiBiome has 11 investors. Key investors include Illumina, SVB, ARE, Locus Biosciences, and Gates Foundation.
Yes. EpiBiome was acquired by Locus Biosciences in July 2018.